ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 571

High Titer Rheumatoid Arthritis Antibodies Distinguish Between PAD2 and PAD4 Citrullinated Fibrinogen

Nathalie Blachere1,2, Salina Parveen1, Mayu Frank1, Brian D. Dill1, Henrik Molina1 and Dana E. Orange1,3,4, 1The Rockefeller University, New York, NY, 2Howard Hughes Medical Institute, Chevy Chase, MD, 3Rheumatology, Hospital for Special Surgery, New York, NY, 4The New York Genome Center, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ACPA, PAD and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Most patients with rheumatoid arthritis (RA) harbor antibodies to citrullinated autoantigens, such as citrullinated fibrinogen. Two isoforms of peptidylarginine deiminase (PAD), PAD2 and PAD4, which catalyze citrullination with different substrate specificities, can be detected in rheumatoid arthritis (RA) synovium. This study was undertaken to determine whether RA patient antibodies preferentially bind PAD2 or PAD4 citrullinated fibrinogen.

Methods: RA patient and normal donor plasma was tested for binding to PAD2 or PAD4 citrullinated fibrinogen, native fibrinogen, or citrullinated fibrinogen peptides in various dilutions by ELISA and Western blot. Bands corresponding to masses demonstrating RA patient reactivity by Western blot were excised and analyzed by mass spectrometry.

Results: As expected, at low titers neither normal donors nor RA patients harbored antibodies to unreactive (native) plasma derived fibrinogen while RA patients harbored significantly elevated antibody to both PAD2 and PAD4 citrullinated fibrinogen. When plasma was further diluted to 1:250 and 1:1000, the OD of RA patient plasma binding of PAD4 citrullinated fibrinogen was significantly greater than PAD2 citrullinated fibrinogen (p<0.01). The ratio of ELISA OD of PAD4 citrullinated fibrinogen divided by PAD2 citrullinated fibrinogen was calculated for each patient. The mean ratios of PAD4/PAD2 citrullinated fibrinogen at the 1:250 and 1:1000 dilutions were 1.26 (95% confidence interval 1.18-1.35) and 1.39 (95% confidence interval 1.24-1.53) respectively, indicating preferential binding of PAD4 citrullinated fibrinogen. RA patient plasma also bound PAD4 citrullinated fibrinogen more than PAD2 citrullinated fibrinogen on Western blot at both 56kD and 76kD (p<0.01 for both bands). Increasing antibody titer associated with increasing avidity (p<0.0001) but there was no difference in avidity for PAD2 or PAD4 citrullinated fibrinogen at low or high titer. Mass spectrometry based analysis of bands corresponding to masses demonstrating RA patient reactivity on western blot identified a hotspot of citrullination of the beta chain of fibrinogen between arginine residues 44 and 74. This hotspot region was modified more heavily than any other site. Both enzymes hypercitrullinated fibrinogen, but PAD4 citrullinates arginines more intermittently, generating peptides with a mix of citrullinated and nonmodifed arginines.

Conclusion: At high titer, RA patient antibodies preferentially bind fibrinogen with a combination of both citrullinated and non-citrullinated arginines.


Disclosure: N. Blachere, None; S. Parveen, None; M. Frank, None; B. D. Dill, None; H. Molina, None; D. E. Orange, None.

To cite this abstract in AMA style:

Blachere N, Parveen S, Frank M, Dill BD, Molina H, Orange DE. High Titer Rheumatoid Arthritis Antibodies Distinguish Between PAD2 and PAD4 Citrullinated Fibrinogen [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/high-titer-rheumatoid-arthritis-antibodies-distinguish-between-pad2-and-pad4-citrullinated-fibrinogen/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-titer-rheumatoid-arthritis-antibodies-distinguish-between-pad2-and-pad4-citrullinated-fibrinogen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology